Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revance Therapeutics (NQ: RVNC ) 6.580 +0.010 (+0.15%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Revance Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 August 01, 2023 From Revance Therapeutics, Inc. Via Business Wire 10 Health Care Stocks With Whale Alerts In Today's Session July 12, 2023 Via Benzinga What 5 Analyst Ratings Have To Say About Revance Therapeutics July 11, 2023 Via Benzinga 7 Healthcare Stocks to Make You the Millionaire Next Door June 21, 2023 For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy. Via InvestorPlace Analyst Expectations for Revance Therapeutics's Future June 07, 2023 Via Benzinga Earnings Preview For Revance Therapeutics May 08, 2023 Via Benzinga 7 Analysts Have This to Say About Revance Therapeutics April 11, 2023 Via Benzinga What 4 Analyst Ratings Have To Say About Revance Therapeutics January 24, 2023 Via Benzinga Revance to Participate in Upcoming Investor Conferences May 23, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update May 09, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023 May 02, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in the Needham 22nd Annual Healthcare Conference April 05, 2023 From Revance Therapeutics, Inc. Via Business Wire 7 Stocks to Buy for the Massive Rally Ahead April 04, 2023 With economic growth poised to exceed expectations in 2023, here are seven stocks to buy for a market rally. Via InvestorPlace Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report March 30, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in Upcoming Investor Conferences March 07, 2023 From Revance Therapeutics, Inc. Via Business Wire Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor March 02, 2023 Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. Via MarketBeat Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update February 28, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director February 28, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance to Participate in the 43rd Annual Cowen Healthcare Conference February 27, 2023 From Revance Therapeutics, Inc. Via Business Wire Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting February 23, 2023 From Revance Therapeutics, Inc. Via Business Wire Earnings Scheduled For February 28, 2023 February 28, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. Via Benzinga Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023 February 21, 2023 From Revance Therapeutics, Inc. Via Business Wire 3 Pharma Stocks That Will Mint Millionaires January 30, 2023 These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. Via InvestorPlace Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook January 19, 2023 Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively. Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session January 11, 2023 Via Benzinga Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors' Attention Today January 09, 2023 Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500... Via Benzinga Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session January 09, 2023 Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session January 09, 2023 Via Benzinga Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday January 09, 2023 U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session. Via Benzinga Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results January 09, 2023 From Revance Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.